<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-06-28">28 June 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Saskia</forename><forename type="middle">J A M</forename><surname>Santegoets</surname></persName>
							<email>s.j.a.m.santegoets@lumc.nl</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical Oncology</orgName>
								<orgName type="institution">Leiden University Medical Center (LUMC)</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eveline</forename><forename type="middle">M</forename><surname>Dijkgraaf</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical Oncology</orgName>
								<orgName type="institution">Leiden University Medical Center (LUMC)</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alessandra</forename><surname>Battaglia</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Catholic University of Sacred Heart</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philipp</forename><surname>Beckhove</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Division of Translational Immunology</orgName>
								<orgName type="department" key="dep2">Department of Surgical Oncology</orgName>
								<orgName type="department" key="dep3">German Cancer Research Center</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cedrik</forename><forename type="middle">M</forename><surname>Britten</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">TRON Translationale Onkologie an der Universitätsmedizin</orgName>
								<orgName type="institution" key="instit2">Johannes Gutenberg-Universität Mainz GmbH</orgName>
								<address>
									<settlement>Mainz</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Immuno-Oncology &amp; Combinations</orgName>
								<address>
									<settlement>Stevenage</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Awen</forename><surname>Gallimore</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Institute of Infection and Immunity</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">Cardiff University</orgName>
								<address>
									<settlement>Cardiff</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrew</forename><surname>Godkin</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Institute of Infection and Immunity</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">Cardiff University</orgName>
								<address>
									<settlement>Cardiff</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cecile</forename><surname>Gouttefangeas</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Immunology</orgName>
								<orgName type="department" key="dep2">Institute for Cell Biology</orgName>
								<orgName type="institution">Eberhard Karls University</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tanja</forename><forename type="middle">D</forename><surname>De Gruijl</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">Vrije Universiteit (VU) University Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hans</forename><forename type="middle">J P M</forename><surname>Koenen</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Laboratory Medicine</orgName>
								<orgName type="laboratory">Laboratory of Medical Immunology</orgName>
								<orgName type="institution">Radboud University Medical Center</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><surname>Scheffold</surname></persName>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Department of Cellular Immunology</orgName>
								<orgName type="department" key="dep2">Clinic for Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité -University Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ethan</forename><forename type="middle">M</forename><surname>Shevach</surname></persName>
							<affiliation key="aff10">
								<orgName type="laboratory">Laboratory of Immunology</orgName>
								<orgName type="institution" key="instit1">National Institute of Allergy and Infectious Diseases</orgName>
								<orgName type="institution" key="instit2">National Institutes of Health</orgName>
								<address>
									<settlement>Bethesda</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Janet</forename><surname>Staats</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Duke Center for AIDS Research</orgName>
								<orgName type="institution">Duke University</orgName>
								<address>
									<settlement>Durham</settlement>
									<region>NC</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">Department of Surgery</orgName>
								<orgName type="institution">Duke University Medical Center</orgName>
								<address>
									<settlement>Durham</settlement>
									<region>NC</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kjetil</forename><surname>Taskén</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Centre for Molecular Medicine Norway</orgName>
								<orgName type="department" key="dep2">Nordic EMBL Partnership</orgName>
								<orgName type="institution" key="instit1">University of Oslo</orgName>
								<orgName type="institution" key="instit2">Oslo University Hospital</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">15 K.G. Jebsen Centre for Cancer Immunotherapy and Biotechnology Centre</orgName>
								<orgName type="institution">University of Oslo</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Theresa</forename><forename type="middle">L</forename><surname>Whiteside</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">University of Pittsburgh Cancer Institute</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Judith</forename><forename type="middle">R</forename><surname>Kroep</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical Oncology</orgName>
								<orgName type="institution">Leiden University Medical Center (LUMC)</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marij</forename><forename type="middle">J P</forename><surname>Welters</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical Oncology</orgName>
								<orgName type="institution">Leiden University Medical Center (LUMC)</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sjoerd</forename><forename type="middle">H</forename><surname>Van Der Burg</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical Oncology</orgName>
								<orgName type="institution">Leiden University Medical Center (LUMC)</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-06-28">28 June 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">C4380676FC0685EC159CF1AD3481133F</idno>
					<idno type="DOI">10.1007/s00262-015-1729-x</idno>
					<note type="submission">Received: 30 March 2015 / Accepted: 30 May 2015 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:14+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>of different markers and context in which Tregs were analyzed.</s><s>This resulted in a rationally composed ranking list of "Treg markers".</s><s>Subsequently, the proposed Treg markers were tested to get insight into the overlap/differences between the most frequently used Treg definitions and their utility for Treg detection in various human tissues.</s><s>Here, we conclude that the CD3, CD4, CD25, CD127, and FoxP3 markers are the minimally required markers to define human Treg cells.</s><s>Staining for Ki67 and CD45RA showed to provide additional information on the activation status of Tregs.</s><s>The use of markers was validated in a series of PBMC from healthy donors and cancer patients, as well as in tumor-draining lymph nodes and freshly isolated tumors.</s><s>In conclusion, we propose an essential marker set comprising antibodies to CD3, CD4, CD25, CD127, Foxp3, Ki67, and CD45RA and a corresponding robust gating strategy for the context-dependent analysis of Tregs by flow cytometry.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Tregs play a key role in the regulation of self-tolerance and the maintenance of tissue homeostasis.</s><s>Several human diseases such as autoimmune and immunodeficient conditions, chronic infections, and cancer have been associated with alterations in Treg numbers or function, and these alterations may contribute to disease progression and impact patient survival <ref type="bibr">[1]</ref><ref type="bibr" target="#b12">[2]</ref><ref type="bibr" target="#b13">[3]</ref>.</s><s>In cancer patients, it is well established that accumulation of Tregs is associated with tumor progression, poor prognosis, and the suppression of anti-tumor immune effector functions.</s><s>Treg-mediated immunosuppression is therefore considered a major obstacle for successful cancer immunotherapy <ref type="bibr" target="#b14">[4]</ref><ref type="bibr">[5]</ref><ref type="bibr">[6]</ref>.</s><s>Given their potential to affect the outcome of immunotherapy trials, Tregs are being studied extensively in this context.</s><s>The multitude of Treg definitions in the reported studies and the lack of functional Treg testing in immunomonitoring of clinical trials, however, make correct interpretation of data and comparisons between studies difficult, especially since knowledge of overlap between the identified Treg populations is missing and the methods to detect these cells differ per laboratory.</s><s>As a result, blurred pictures emerge with respect to associations between clinical outcome and Tregs <ref type="bibr" target="#b17">[7]</ref>.</s><s>So far, Tregs have been identified through a number of different (combinations of) markers including CD4 pos , Foxp3 pos/hi , CD25 pos/hi , CD127 neg/low , CTLA-4 pos , CD45RA pos/neg , Helios pos , CD39 pos , and CD73 pos/neg using several different gating strategies <ref type="bibr">[8]</ref><ref type="bibr" target="#b19">[9]</ref><ref type="bibr" target="#b20">[10]</ref><ref type="bibr">[11]</ref><ref type="bibr">[12]</ref><ref type="bibr">[13]</ref><ref type="bibr" target="#b24">[14]</ref><ref type="bibr" target="#b25">[15]</ref>.</s><s>The latter may form an important addition to misinterpretation of data sets since differences in gating strategies were found to be the biggest source for interassay variation in flow cytometry-based intracellular cytokine staining (ICS) assays <ref type="bibr">[16,</ref><ref type="bibr">17]</ref>.</s><s>Similarly, a lack of adequate controls to guide the settings of gates may add another level of complexity to the analysis of Tregs.</s></p><p><s>To address these issues, the CIP organized a workshop on October 29, 2013 on the detection and functional testing of Tregs.</s><s>This workshop, which hosted 40 researchers from seven countries in Europe and the USA, brought together leading experts in the field to <ref type="bibr">(1)</ref> understand the state of the art of Treg research and to (2) define the most appropriate assays/markers to measure, quantify, and functionally assess Tregs within patient samples.</s><s>As it became apparent during the workshop that a multitude of markers and combinations thereof is currently being used by the participants, a rationally composed ranking list of "Treg markers" was generated by the participants in the follow-up of the meeting.</s><s>The preparation of this Treg marker list, subsequent data interpretation of the experiments performed at the LUMC, and subsequent discussions about and approval of the final conclusions were done through a series of circulating emails.</s><s>Subsequently, the proposed Treg markers were tested in order to get insight into the overlap/differences between the most frequently used Treg definitions and their utility for Treg detection in various human tissues.</s><s>This led to a context-dependent [i.e., peripheral blood/ tumor/lymph node (LN)] essential marker set and robust gating strategy for the analysis of Tregs by flow cytometry.</s></p><p><s>for human T cell assays <ref type="bibr" target="#b28">[18]</ref>.</s><s>Venous blood samples of healthy donors (HD) and recurrent ovarian cancer (OvCa) patients undergoing chemo-immunotherapeutic treatment (EM Dijkgraaf et al. submitted for publication) were drawn into sodium heparin collection tubes (Greiner Bio-one, Alphen a/d Rijn, the Netherlands) after signing informed consent.</s><s>PBMCs were isolated using Ficoll (LUMC pharmacy, Leiden, the Netherlands) density gradient centrifugation, washed with PBS (B.</s><s>Braun, Melsungen, Germany), cryopreserved in 90 % fetal calf serum (FCS; PAA Laboratories, Pasching, Austria) and 10 % DMSO (Sigma-Aldrich, St. Louis, MO, USA), and stored in the vapor phase of liquid nitrogen until further use <ref type="bibr" target="#b29">[19]</ref>.</s><s>TDLN and tumor samples were obtained from cervical cancer patients (CxCa) within the CIRCLE study after signed informed consent.</s><s>The CIRCLE study investigates cellular immunity against HPV in HPV-induced (pre)malignant lesions and was approved by the Medical Ethical Committee of the LUMC <ref type="bibr">[20]</ref>.</s><s>Single-cell suspensions were prepared from TDLN and tumor samples using collagenase/ DNase digestion or gentle MACS procedure, respectively.</s><s>First, TDLN and tumor samples were cut into small pieces.</s><s>Single-cell suspensions were prepared by incubating the TDLN pieces with 250 U/ml collagenase D (Roche, Almere, the Netherland) and 50 µg/ml DNase I (Roche) for 1 h at 37 °C, after which the TDLN was put through a cell strainer <ref type="bibr">[21]</ref>.</s><s>Single-cell suspensions of tumor samples were prepared by incubating the tumor pieces for half an hour at 37 °C in IMDM/10 % human AB serum (Greiner) supplemented with 50 µg/ ml gentamycin (Life technologies, Bleiswijk, the Netherlands), 25 µg/ml Fungizone (Life Technologies), 10 % penicillin/streptomycin (Sigma), 1 mg/ml collagenase D, and 50 µg/ml DNAse I (dissociation mix), followed by gentleMACS dissociation procedure according to the manufacturers' instructions.</s><s>Next, cells were frozen and stored as above.</s><s>The handling and storage of the PBMC, TDLN, and tumor samples were done according to the standard operation procedures (SOP) of the department of Clinical Oncology at the LUMC by trained personnel.</s><s>The use of the above-mentioned patient materials was approved by the Medical Ethics Committee Leiden in agreement with the Dutch law for medical research involving humans.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treg enumeration by flow cytometry</head><p><s>The cryopreserved cell samples were thawed according to SOPs and as described before <ref type="bibr" target="#b29">[19]</ref>, and Treg subsets were assessed by flow cytometry staining.</s><s>To this end, one million PBMCs or ~250,000-750,000 TDLN or tumor sample cells was used per condition.</s><s>Since it has been described that Foxp3 staining can be highly variable and depend on the choice of antibody (clone), buffer, and/or fluorochrome <ref type="bibr" target="#b32">[22]</ref><ref type="bibr" target="#b33">[23]</ref><ref type="bibr" target="#b34">[24]</ref> and the performance of a specific antibody is optimized by the manufacturer using their own permeabilization procedures, optimal Foxp3 staining was determined first.</s><s>We selected four different Foxp3 antibodies on the basis of in-house availability, compatibility with the rest of our panel and with the LSR Fortessa optical configuration, and two different intranuclear staining kits.</s><s>Optimal staining was determined by the analysis of the percentage of positive cells and at the strength of the positive signal (compared to the negative fluorescence minus one (FMO) signal).</s><s>Antibodies and intranuclear staining kits used for Foxp3 staining setup were AF700-labeled Foxp3 (clone PCH101, eBiosciences), PE-labeled Foxp3 (clone PCH101, eBiosciences, and clone 206D, R&amp;D systems), PE-CF594-labeled Foxp3 (clone 259D/C7, BD), AmCyan-labeled CD3 (clone SK7, BD), V500-labeled CD3 (clone UCHT1, BD), PE-CF594-or AF700-labeled CD4 (both clone RPA-T4, BD), PE-CY7-labeled CD25 (clone 2A3, BD), BV650labeled CD127 (clone HIL-7R-M21, BD), the Foxp3/ transcription factor staining buffer set (eBiosciences), and the BD Pharmingen Transcription Factor Buffer set (BD).</s><s>Cell surface antibody staining was performed in PBS/0.5 % BSA/0.02</s><s>% sodium azide (PBA) buffer for 30 min at 4 °C.</s><s>Intranuclear Foxp3 staining was conducted with the BD or eBiosciences Transcription Factor Buffer sets according to the manufacturers' protocol.</s><s>Analysis revealed that Foxp3 could be detected with all used clones when using the eBiosciences kit.</s><s>Yet, staining intensity (and thus discrimination between negative and positive) was lower with the PCH101 clones when compared with the 206D (PE) clone (Supplementary figure <ref type="figure" target="#fig_0">1a-c</ref>), which may be due to fluorochrome choice.</s><s>Staining pattern and positive-to-negative signal ratio [i.e., staining index (SI)] of the 259D/ C7 (PE-CF594) clone were most optimal with the BD TF kit (not shown) and were comparable to the staining pattern of the 206D clone using this kit, indicating that both antibodies could be used in our Treg panel (Supplementary figure <ref type="figure" target="#fig_0">1d-f</ref>).</s><s>After selection of the best Foxp3 antibody and intranuclear staining buffer set, all additional antibodies in the final panel were titrated, and spillover profiles were generated to ascertain that there was no spectral overlap of the selected antibodies into the secondary detectors.</s><s>Optimal antibody concentrations were determined based on the following criteria: (a) frequency and (b) highest SI (positive mean divided by negative mean), and spillover profiles were generated as described by Murdoch et al. <ref type="bibr" target="#b35">[25]</ref>.</s><s>Antibodies and kits used in the final panel were V500-labeled CD3 (clone UCHT1, BD), AF700-labeled CD4 (clone RPA-T4, BD), PE-CY7-labeled CD25 (clone 2A3, BD), BV650-labeled CD127 (clone HIL-7R-M21, BD), APC-H7-labeled CD45RA (clone HI100, BD), PerCP-Cy5.5labeled</s><s>CD8 (clone SK1, BD), PE-CF594-labeled Foxp3 (clone 259D/C7, BD), BV421-labeled CTLA-4 (clone BNI3, BD), FITC-labeled Ki67 (clone 20Raj1, eBiosciences), APC-labeled Helios (clone 22F6, Biolegend), PE-labeled CD39 (clone ebioA1, eBiosciences), LIVE-DEAD ® Fixable yellow dead cell stain kit (Q-dot585, Life technologies), and the BD Pharmingen Transcription Factor Buffer set.</s><s>Stained cells were acquired on a LSR Fortessa (BD) and analyzed using DIVA software version 6.2.</s><s>Events collected were generally &gt;200,000 per sample, except for one tumor-infiltrating lymphocyte (TIL) sample (~35,000 cells).</s><s>In the latter, still adequate numbers (~400) of Tregs could be detected.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treg definitions and gating strategies</head><p><s>Tregs were analyzed according to three commonly used Treg definitions in the literature: (1) the CD25 pos CD-127 low Foxp3 pos subset [definition 1 (def.1)]</s><s>[9, 10], (2) the Foxp3 pos Helios pos Treg subset (def.2) <ref type="bibr">[12,</ref><ref type="bibr" target="#b36">26]</ref>, and (3) the Foxp3 hi CD45RA neg activated Treg (aTreg) and Fox-p3 int CD45RA pos naïve Treg (nTreg) subsets (def.3)</s><s><ref type="bibr">[8,</ref><ref type="bibr">11]</ref>.</s><s>Gating for CD25 and CD127 (def.1),</s><s>Foxp3 and Helios (def.2), and Foxp3 and CD45RA (def.3)</s><s>Tregs was done on CD3 pos CD4 neg (i.e., CD8 pos ) T cells and CD3 neg lymphocytes, respectively, and subsequently applied to CD3 pos CD-4 pos T cells (see also supplementary figure <ref type="figure" target="#fig_3">2a, 3a, and 5a</ref>).</s><s>Percentage of def.1, def.2, or def.3 Tregs is given as percentage within the CD4 pos population.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Nonparametric (Wilcoxon signed-rank or Mann-Whitney test for two samples and Friedman or Kruskal-Wallis with Dunn's multiple comparison test for multiple samples) and parametric (paired or unpaired t test for two samples or RM one-way ANOVA or ordinary one-way ANOVA with Tukey's multiple comparison test for multiple samples) tests were performed as appropriate.</s><s>All statistical tests were performed at the 0.05 significance level, and 95 % confidence intervals were two-sided intervals.</s><s>For survival analysis, the OvCa patients undergoing chemo-immunotherapeutic therapy were grouped into two groups according to the median (i.e., grouped into below or above the median of the total group for each parameter), after which survival was tested using Kaplan-Meier method, and statistical significance of the survival distribution was analyzed by log-rank testing.</s><s>Statistical analyses were performed using SPSS for Windows version 20.0 (IBM, USA) and Graph-Pad Prism 6.02 (San Diego, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Generation of a rationally ranked Treg marker list</head><p><s>During the CIP workshop, a number of Treg analysis methods were presented.</s><s>These analyses were discussed, a number of questions were formulated, and during the follow-up of the meeting, a rationally composed ranking list of "Treg markers" was generated.</s><s>All markers suggested, and the rationale to use them is given in Table <ref type="table" target="#tab_0">1</ref>.</s><s>To test these markers and get insight into the overlap/differences between the most frequently used human Treg definitions, we included markers 1-8, 10, and 11 for direct ex vivo analysis of peripheral blood samples from six HD and OvCa patients, and LN and tumor samples obtained from CxCa patients.</s><s>Markers were included based on the number of participants opting for inclusion of the marker and/or their known association with Tregs.</s><s>LAP/GARP (number 9) was excluded as this marker is only expressed &gt;24 h following in vitro activation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Tregs according to commonly used Treg definitions</head><p><s>Tregs were analyzed according to three commonly used Treg definitions in the literature <ref type="bibr">[8]</ref><ref type="bibr" target="#b19">[9]</ref><ref type="bibr" target="#b20">[10]</ref><ref type="bibr">[11]</ref><ref type="bibr">[12]</ref><ref type="bibr" target="#b36">26]</ref>.</s><s><ref type="figure">2b, c</ref>), enumerating def.1 Tregs solely based on CD25 and CD127 is highly variable between HD and most likely leads to an overestimation of the number of Tregs (mean 17.6 %, range 7.2-30.4</s><s>%).</s><s>Inclusion of Foxp3 resulted in less variation in the percentage of def.1 Tregs (mean 6.9 %, range 4.6-8.8</s><s>%) as would be expected among a group of HD, suggesting that simultaneous staining with CD25, CD127, and Foxp3 is needed for reliable measurement of def.1 Tregs.</s><s>Further characterization of the CD25 pos CD127 low Foxp3 pos subset revealed that 75 % of these cells were Helios positive (Fig. <ref type="figure" target="#fig_0">1a</ref>).</s><s>Moreover, the majority of CTLA-4 and Ki67 expressing CD4 pos T cells were found in the CD25 pos CD127 low Foxp-3 pos population (data not shown).</s><s>These observations add to the notion that bona fide Tregs are detected when the CD25 pos CD127 low Foxp3 pos def.1 subset definition for Treg enumeration is used.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definition 2: Foxp3 pos Helios pos Tregs</head><p><s>The gating strategy for the Foxp3 pos Helios pos def.2 Treg subset is given for a representative HD in supplementary figure 3a.</s><s>Analysis revealed that 5.6 % of CD4 pos T cells is Foxp3 pos Helios pos (range 4.1-7.1 %), and Foxp3 pos Helios neg cells accounted for 2.9 % (range 1.9-4.4</s><s>%) of CD4 pos T cells.</s><s>Interestingly, Foxp3 expression of Foxp3 pos Helios neg cells was significantly lower than that of Foxp3 pos Helios pos cells (Supplementary figure <ref type="figure" target="#fig_3">3b,  c</ref>).</s><s>Further characterization of the def.2</s><s>Treg subsets revealed that the majority of the Foxp3 pos Helios pos cells (mean 88 %, range 84.7-90.7 %) were found inside the CD25 pos CD127 low def.1 Treg subset (Supplementary figure <ref type="figure" target="#fig_4">4</ref>).</s><s>Moreover, 64 % of Foxp3 pos Helios neg cells (range 52.0-72.9</s><s>%) could also found within that CD25 pos CD-127 low gate.</s><s>Expression levels of CTLA4 and CD45RA were found similar in Foxp3 pos Helios neg and Foxp3 pos Helios pos cells (Fig. <ref type="figure" target="#fig_0">1b</ref>).</s><s>Together, this indicates that although probably polluted with Foxp3 pos activated effector T cells, the population of Foxp3 pos Helios neg cells also contain considerable amounts of Tregs according to definition 1.</s><s>Interestingly, Foxp3 pos Helios pos cells expressed significantly more Ki67 compared with Foxp3 pos Helios neg cells, suggesting that Foxp3 pos Helios pos cells, which also express higher levels of Foxp3, represent more recently activated Tregs (p = 0.03; Fig. <ref type="figure" target="#fig_0">1b</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definition 3: Foxp3 hi CD45RA neg a Treg and Foxp3 int CD45RA pos n Tregs</head><p><s>The gating strategy for the Foxp3 hi CD45RA neg and Foxp3 int CD45RA pos def.3 Treg subsets is given for a representative HD in supplementary figure <ref type="figure">5a</ref>.</s><s>Fox-p3 hi CD45RA neg aTreg accounted for 1.1 % (range 0.8-1.6 %) and Foxp3 int CD45RA pos nTreg for 1.4 % (range 0.6-2.5 %) of CD4 pos T cells.</s><s>Remarkably, the so-called Foxp3 int CD45RA neg non-Treg subset accounted for 6.0 % (range 4.2-7.4</s><s>%) of CD4 pos T cells, and this was significantly more than the aTreg and nTreg frequencies detected (p &lt; 0.001) (Supplementary figure <ref type="figure">5b</ref>).</s><s>Further characterization revealed that the majority of aTregs and nTregs could be found within the CD25 pos CD127 low def.</s><s><ref type="figure">6a, b, d</ref>).</s><s>Moreover, the frequency of def.1 or def.2 Tregs within the non-Treg population was significantly higher than within the aTreg and nTreg populations (Supplementary figure <ref type="figure">6a, c, e</ref>).</s><s>As expected, the aTreg, but not the nTreg population, displayed an activated profile indicated by high levels of Ki67 and CTLA4 expressions (% and mean fluorescence intensity; Fig. <ref type="figure" target="#fig_0">1c</ref> and data not shown, respectively) sustaining the notion that this preset profile is likely to accurately detect activated Tregs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Expression of ectonucleoside triphosphate diphosphohydrolase-1 (CD39)</head><p><s>It has been described that human Tregs express CD39, an ectonucleotidase involved in adenosine triphosphate (ATP) breakdown and the production of immunosuppressive adenosine, thereby suggesting that CD39 may be a functional marker on Tregs <ref type="bibr" target="#b37">[27,</ref><ref type="bibr" target="#b38">28]</ref>.</s><s>To study the expression of CD39 in relation to the three commonly used Treg definitions, CD39 was included in our flow cytometric marker panel, and two HD-derived PBMC samples were analyzed.</s><s>Although the majority of CD39 can be found in CD25 pos CD127 low Foxp3 pos def.1 Tregs (~70 %), expression of CD39 is not def.1 Treg exclusive (Supplementary figure <ref type="figure">7a, d</ref>).</s><s>Similar results were found for Foxp3 pos Helios pos def.2 Treg and the Foxp3CD45RA def.3 Treg subsets (Supplementary figures 7b, c, e, f).</s><s>Interestingly and indeed suggestive of their functional potential, CD39 expression is much higher in Foxp3 hi CD45RA neg aTregs than in Foxp3 int CD45RA pos nTregs.</s><s>Thus, CD39 expression seems to be present especially on activated Tregs, but its expression is not Treg exclusive.</s><s>Within the activated Treg populations, it identifies the same population of cells, that is, CD45RA neg and CTLA4 pos .</s><s>CD39 expression therefore falls into the category of markers for identifying the activated subset of Tregs.</s><s>Of note, it has been demonstrated that CD39, when combined with CD25, can be used to identify and isolate Tregs with strong suppressive activity <ref type="bibr" target="#b40">[29,</ref><ref type="bibr" target="#b41">30]</ref>.</s><s>Gating on the cell surface markers CD25 pos , CD127 low , and CD39 pos yielded 75-80 % Foxp3 pos cells in our hands (Supplementary figures <ref type="figure">7 and 8</ref>).</s></p><p><s>Based on the expression of high levels of CD25, Helios, CTLA-4, and CD39, the CD25 pos CD127 low Foxp3 pos def.1, Foxp3 pos Helios pos def.2, and Foxp3 hi CD45RA neg def.3 T cells were classified as bona fide Tregs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overlap between the three Treg definitions</head><p><s>Next, the overlap between the def.1, def.2, and def.3 Tregs was determined (Fig. <ref type="figure">2a-c</ref>).</s><s>As expected, there was considerable overlap between the three Treg definitions.</s><s>The overlap between the CD25 pos CD127 low Foxp3 pos def.1 Tregs and the Foxp3 pos Helios pos def.2 Tregs is approximately 73 %, and thus, Treg enumeration based solely on Foxp3 and Helios may lead to an underestimation in Tregs of ~27 % through exclusion of CD25 pos CD127 low Foxp-3 pos cells in the Foxp3 pos Helios neg population (range 20.2-35.3 % of CD25 pos CD127 low Foxp3 pos Tregs; supplementary figure <ref type="figure" target="#fig_4">4c</ref>).</s><s>Furthermore, Treg measurements based solely on Foxp3 and CD45RA (def.3)</s><s>led to an underestimation of the number of def.1 Tregs of 67.5 % through exclusion of the so-called Foxp3 int CD45RA neg non-Tregs (range</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treg enumeration in PBMC, TDLN, and TIL of cancer patients</head><p><s>It has been described that the expression of CD25 and/ or CD127 can be altered in (chronic) inflammatory/autoimmune diseases such as systemic lupus erythematosus (SLE) and type 1 diabetes, thereby influencing reliable Treg enumeration <ref type="bibr">[12,</ref><ref type="bibr" target="#b36">26,</ref><ref type="bibr" target="#b42">31]</ref>.</s><s>In addition, changes in CD25 and CD127 expressions have also been observed in cancer patients undergoing immunotherapeutic interventions such as vaccination or ipilimumab treatment <ref type="bibr" target="#b43">[32]</ref><ref type="bibr" target="#b44">[33]</ref><ref type="bibr" target="#b45">[34]</ref><ref type="bibr" target="#b46">[35]</ref>.</s><s>To study the possibility of analyzing Tregs by the different definitions under such conditions, we analyzed peripheral blood samples from patients with recurrent OvCa and TDLN and tumor samples from CxCa patients.</s></p><p><s>As shown in Fig. <ref type="figure" target="#fig_3">3</ref> for representative examples, the gating and enumeration of Tregs based on CD25, CD127, Foxp3 (def.1), and Foxp3 and Helios (def.2) is feasible in OvCa-derived peripheral blood, as well as in TDLN and tumor samples from CxCa patients using the same gating strategy applied for HD-derived PBMC.</s><s>Treg enumeration based on def.3 was feasible in peripheral blood and TDLN samples of patients but was not reliable in tumor samples due to the absence of the Foxp3 int CD45RA pos nTreg population which is used for discrimination between Foxp3 int and Foxp3 hi cells in the gating strategy (see also Supplementary figure <ref type="figure">5</ref> for Foxp3 and CD45RA gating strategy).</s><s>Figure <ref type="figure" target="#fig_3">3b</ref> shows a summary of the detected Treg frequencies in all analyzed samples.</s><s>Importantly, the overlap between the three Treg subsets was comparable between HD-derived and OvCa patient-derived peripheral blood, CxCa-derived TDLN and tumor samples (Supplementary figure <ref type="figure">9</ref>), indicating that CD25, CD127, and Foxp3 can also be used in cancer condition tissues.</s><s>Of note, the additional value of CD127 and CD25 in the def.1 Treg marker set becomes particularly clear upon exclusion of these markers when assessing Treg frequencies in these samples.</s><s>Exclusion of CD127 and/or CD25 from the Treg panel resulted in increase in the number of detected def.1 Tregs (supplementary figure <ref type="figure" target="#fig_0">10</ref>).</s><s>Although exclusion of CD127 only led to a substantial increase in the frequency of def.1 Tregs (mean 21.5 %, range 14.7-29.3</s><s>%) in the PBMC of OvCa patients, exclusion of CD25 or CD25 and CD127 led to substantial increases in the frequency of these def.1 Tregs in PBMC of HD and OvCa patients as well as in TDLN or tumor samples from CxCa patients (17.9, 21.9, 24.0, and 30.8 % for CD25 exclusion and 37.6, 58.8, 40.4,</s><s>and 43.3 % for CD25 and CD127 exclusions, see supplementary figure <ref type="figure" target="#fig_0">10a</ref>).</s><s>This resulted from a less pure Treg detection as reflected by lower percentage of def.1 Tregs expressing markers such as CTLA-4 and reduced frequencies of Helios pos def.2 and Foxp3 hi CD45RA neg def.3 aTreg cells among the def.1 Tregs (supplementary figure <ref type="figure" target="#fig_0">10b</ref>), indicating that CD25 and CD127 are required for reliable assessment of def.1 Tregs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The association between Tregs and survival</head><p><s>Treg accumulation in the tumor or peripheral blood is associated with tumor progression and poor prognosis <ref type="bibr" target="#b13">[3]</ref><ref type="bibr" target="#b14">[4]</ref><ref type="bibr">[5]</ref><ref type="bibr">[6]</ref>.</s><s>To study the relation between the different Treg subsets and survival, we determined the frequencies of the def.1, def.2, and def.3 Tregs in the PBMC of recurrent OvCa patients undergoing chemo-immunotherapeutic treatment (EM Dijkgraaf et al. submitted for publication) and correlated these levels to the overall survival (OS).</s><s>Pretreatment levels of none of the def.1 Tregs, def.2 Tregs, and def.3 aTreg correlated with survival (Fig. <ref type="figure" target="#fig_4">4a</ref>).</s><s>However, when the pretreatment frequencies of Fox-p3 hi CD45RA neg or Ki67 pos cells within def.1 Tregs (i.e., activated def.1 Tregs) were determined, a trend toward reduced OS was observed for patients with high frequencies of Foxp3 hi CD45RA neg def.1 Tregs (p = 0.0643) and a significant reduced OS for patients with high frequencies of Ki67 pos def.1 Tregs (p = 0.0133; Fig. <ref type="figure" target="#fig_4">4b</ref>).</s><s>The latter suggests that in particular, measurements of a more activated Treg pool may have prognostic or predictive value.</s><s>Gates for Foxp3 hi CD45RA neg and Ki67 pos were set as shown in the FACS plots.</s><s>Patients were grouped into two groups based on the median of the total population, i.e., into a group of patients with frequencies that were below the median (dotted line) or with frequencies above the median (solid line) for the indicated parameter, after which survival analysis was performed.</s><s>Number of patients and corresponding OS for each group is given.</s><s>Statistical analysis was performed by log-rank testing, and differences were considered significant when p &lt; 0.05 robust, undisputable, and context (tissue)-independent gating since differences in gating strategies have been found to be the biggest source for interassay variation in flow cytometry-based assays <ref type="bibr">[16,</ref><ref type="bibr">17]</ref>.</s><s>Fourth, if possible, one should be able to assess their functionality.</s></p><p><s>Based on the data presented here and taking into account the above-mentioned considerations, we consider the use of the CD3, CD4, CD25, CD127, and Foxp3 markers as the minimally required markers to define human Tregs.</s><s>We showed that this combination of markers allows for robust and undisputable gating of Tregs in the context of HD-and cancer patient-derived peripheral blood as well as TDLN and tumor samples (Supplementary figure <ref type="figure">2</ref> and Fig. <ref type="figure" target="#fig_3">3</ref>).</s><s>Although the latter also holds true for Foxp3 pos Heliospos def.2 Tregs (Supplementary figure <ref type="figure" target="#fig_3">3</ref> and Fig. <ref type="figure" target="#fig_3">3</ref>), Treg measurement based solely on Foxp3 and Helios resulted in a ~25 % underestimation of the number of def.1 Tregs through exclusion of CD25 pos CD127 low cells within the Foxp3 pos Helios neg population in all tested tissues/compartments (supplementary figure <ref type="figure" target="#fig_4">4 and 9</ref>).</s><s>These observations were in line with findings from others, reporting that Helios expression was restricted to a subpopulation (approximately 70 %) of human Foxp3 pos T(reg) cells <ref type="bibr">[12,</ref><ref type="bibr">13,</ref><ref type="bibr" target="#b36">26]</ref>.</s><s>Treg enumeration based on Foxp3 and CD45RA (def.3)</s><s>yielded distinctive aTreg and nTreg populations in HDand cancer patient-derived peripheral blood and TDLN, with high CD25, CTLA-4, and Ki67 expression levels in the aTreg and lower expression levels of these markers in the nTreg populations (Supplementary figure <ref type="figure">6</ref> and figure <ref type="figure" target="#fig_3">1  and 3</ref>).</s><s>Yet, in line with findings from others <ref type="bibr">[12]</ref>, the largest population of CD25 pos CD127 low Foxp3 pos (def.1;</s><s>supplementary figure <ref type="figure">6c</ref>) or Foxp3 pos Helios pos (def.2;</s><s>supplementary figure <ref type="figure">6e</ref>) populations was found in the so-called non-Treg population of Foxp3 int CD45RA neg cells.</s><s>While the population of Tregs based on definitions 1 or 2 may contain small fractions on non-Tregs, the measurement of Tregs based solely on Foxp3 and CD45RA (def.3) will lead to a ~60-70 % underestimation of Tregs.</s><s>Importantly, def.3 Treg gating could not be done in a robust and undisputable fashion in tumor samples.</s><s>Although not unexpected and observed before <ref type="bibr">[8]</ref>, the absence of the Foxp3 int CD45RA pos T cell population in tumor samples precluded robust def.3 aTreg and nTreg gatings in this context.</s><s>Notably, the apparent absence of naïve T cells at tumor effector sites and the preferential recruitment of activated Tregs or accumulation of locally activated Tregs does confirm the validity of the defined respective activated and naïve Treg definitions within definition 3 <ref type="bibr">[8,</ref><ref type="bibr">11]</ref>.</s><s>Of note, this observation clearly emphasizes the need for validating/assessing the suitability of the flow cytometry panels in the intended context/tissue.</s></p><p><s>As shown, we used CD3 pos CD4 neg (i.e., CD8 pos ) and CD3 neg cells to define the limits of the positive (CD25, CD127, Helios, and CD45RA) gates as this has been described to form a more reliable gating strategy than using isotype control antibodies or FMO controls <ref type="bibr" target="#b33">[23]</ref>.</s><s>Omission of CD3 and CD8 antibodies from the essential marker set does affect our gating strategy resulting in less reliable/ more disputable CD25, CD127, Helios, and CD45RA gating, and thus affecting the reliability of our results (data not shown).</s><s>Furthermore, this gating strategy results in objective CD25 pos gating rather than subjective CD25 high gating, the latter being very important for harmonized and comparative Treg analysis.</s></p><p><s>There are a number of Treg-associated markers which we consider to be of interest, yet optional to the required minimal panel.</s><s>Based on our data, we highly recommend extending the minimally required antibody panel to include Ki67 and CD45RA as they provide additional information on the Treg activation status (Table <ref type="table" target="#tab_2">2</ref>).</s><s>Indeed, the addition of CD45RA and Ki67 to the marker panel proved very informative in that no def.1,</s><s>def.2, or def.3 Tregs were associated with worse survival of ovarian cancer patients but only the pretreatment frequencies of activated Foxp-3 pos CD45RA neg and Ki67 pos def.1 Tregs (Fig. <ref type="figure" target="#fig_4">4</ref>).</s><s>The measurement of activated Ki67 pos Tregs has also been advocated by others <ref type="bibr" target="#b47">[36,</ref><ref type="bibr" target="#b48">37]</ref>.</s><s>In one study, renal cell cancer patients undergoing multipeptide vaccination and cyclophosphamide treatment showed a significant reduction in the number of circulation Ki67 pos Tregs and a trend toward prolonged OS following therapy <ref type="bibr" target="#b48">[37]</ref>.</s><s>Of note, as Ki67 pos def.1 Treg detection was also feasible in TDLN and tumor samples (not shown), this strategy may also be useful to identify activated Tregs within def.1 Tregs in tumor samples, thereby circumventing the need for the subjective gating on Foxp3 hi versus Foxp3 int cells.</s><s>While the activation markers CD39 and CTLA-4 <ref type="bibr" target="#b37">[27,</ref><ref type="bibr" target="#b38">28,</ref><ref type="bibr" target="#b49">38,</ref><ref type="bibr" target="#b50">39]</ref> have been described as functional markers to identify activated Tregs, they do not provide additional information to a panel over CD45RA and Ki67 and the minimally required antibody set.</s><s>Helios may be of interest for identifying Tregs in autoimmunity such as SLE since these patients' conventional T cells display high levels of CD25 resulting in overlap with Tregs <ref type="bibr">[12]</ref>.</s><s>In a recent trial where patients displayed a strong antigen-specific CD4 pos T cell response to vaccination, we did not observe such problems for identifying Tregs using the currently proposed markers (EM Dijkgraaf et al. submitted for publication).</s><s>Based on our data, omission of CD25 as a marker is not recommended as this resulted in the identification of less pure Treg populations (Supplementary figure <ref type="figure" target="#fig_0">10</ref>).</s><s>In addition, there remains a number of markers, not tested in this study, which may offer benefits to identify specific subsets of Tregs.</s><s>CD147 is a cell surface marker that is accessible directly ex vivo and can also be used to identify an activated and highly suppressive Treg subset <ref type="bibr" target="#b47">[36,</ref><ref type="bibr" target="#b51">40,</ref><ref type="bibr" target="#b52">41]</ref>.</s><s>Furthermore, LAP (membrane-bound active form of TGF-β) and GARP (membrane-anchoring molecule involved in latent TGF-β binding) may be particularly interesting in defining TGF-β-associated and activated Tregs in tumor samples <ref type="bibr" target="#b50">[39,</ref><ref type="bibr" target="#b53">[42]</ref><ref type="bibr" target="#b54">[43]</ref><ref type="bibr" target="#b55">[44]</ref><ref type="bibr" target="#b56">[45]</ref>.</s><s>Moreover, the chemokine receptors CCR6, CXCR3, CCR4, and CCR10 were found to be useful for the identification of phenotypical and functional distinct subsets of human Foxp3+ Tregs <ref type="bibr" target="#b57">[46]</ref>.</s></p><p><s>In summary, consensus was reached concerning the use of an essential marker set comprising antibodies to CD3, CD4, CD25, CD127, Foxp3, Ki67, and CD45RA and a corresponding robust gating strategy for the analysis of Tregs in human samples.</s><s>This set will be used in proficiency panels to harmonize the phenotypic analysis of Tregs within laboratories participating in the CIP.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Definition 1 :</head><label>1</label><figDesc><div><p><s>Figure1ashows the expression of the different markers in def.1 Tregs.</s><s>The gating strategy for the CD25 pos CD-127 low Foxp3 pos def.1 Treg subset is given for a representative HD in supplementary Fig.2a.</s><s>Cells expressing Foxp3 comprised 78.7 % (range 70.5-85.1 %) of the CD25 pos CD-127 low subpopulation.</s><s>Due to variability in CD127 expression (Supplementary figure2b, c), enumerating def.1 Tregs solely based on CD25 and CD127 is highly variable between HD and most likely leads to an overestimation of the number of Tregs (mean 17.6 %, range 7.2-30.4</s><s>%).</s><s>Inclusion of Foxp3 resulted in less variation in the percentage of def.1 Tregs (mean 6.9 %, range 4.6-8.8</s><s>%) as would be expected among a group of HD, suggesting that simultaneous staining with CD25, CD127, and Foxp3 is needed for reliable measurement of def.1 Tregs.</s><s>Further characterization of the CD25 pos CD127 low Foxp3 pos subset revealed that 75 % of these cells were Helios positive (Fig.1a).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>surface Expressed on activated, tumor antigen-specific T cells in cancer patients (bone marrow and peripheral blood)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 1 Fig. 2</head><label>12</label><figDesc><div><p><s>Fig. 1 CD25 pos CD127 low Foxp3 pos def.1, Foxp3 pos Helios pos def.2, and Foxp3 hi CD45RA neg def.3 aTregs express high levels of Tregassociated markers, suggesting that they are bona fide Tregs.</s><s>Phenotypic characterization of def.1, def.2, and def.3 Tregs was performed by flow cytometry.</s><s>Gating of the three different Treg definitions was performed as described in supplementary figs.</s><s>2a, 3a, and 5a.</s><s>Expression of the Treg-associated markers Helios, CD45RA, CTLA4, Ki67, and CD39 is depicted for a representative healthy donor (HD; left) and multiple HD (right; Helios/CD45RA/CTLA4/Ki67 for six and</s></p></div></figDesc><graphic coords="6,53.86,57.76,487.56,454.44" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 3</head><label>3</label><figDesc><div><p><s>Fig. 3 Treg gating based on Foxp3 and CD45RA (def.3) is subjective in TIL as it is difficult to distinguish between Foxp3 hi versus FoxP3 low cells due to the absence of Foxp3 int CD45RA pos population.</s><s>Def.1, def.2, and def.3 Treg analyses were performed by flow cytometry.</s><s>Treg analysis based on CD25 and CD127 (def.1),</s><s>FoxP3 and Helios (def.2), and FoxP3 and CD45RA (def.3) is given for PBMC of a representative healthy donor (HD) and an ovarian cancer (OvCA) patient and for a TDLN and TIL sample of representa-</s></p></div></figDesc><graphic coords="9,85.06,57.76,425.16,554.76" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. 4</head><label>4</label><figDesc><div><p><s>Fig.<ref type="bibr" target="#b14">4</ref> High pretreatment frequencies of Foxp3 hi CD45RA neg and Ki67 pos def.1 Tregs (i.e., activated def.1 Tregs) are associated with reduced overall survival in OvCa patients undergoing chemoimmunotherapeutic therapy.</s><s>The use of Ki67 and CD45RA provides additional information on the activation status of def.1 Tregs.</s><s>Treg analysis was performed based on CD25, CD127, and Foxp3 (def.1),</s><s>Foxp3 and Helios (def.2), and Foxp3 and CD45RA (def.3) in PBMC of 21 chemo-immunotherapy-treated ovarian cancer (OvCA) patients (EM Dijkgraaf et al., submitted for publication).</s><s>Pretreatment values of def.1, def.2, and def.3 Tregs were determined, and overall survival (OS) of these patients following chemo-immunotherapy was plotted in Kaplan-Meier curves for pretreatment values of def.1 (left), def.2 (middle), and def.3 (right) Tregs in a. Activation status of def.1 Tregs was determined by measuring the frequency of Fox-p3 hi CD45RA neg and Ki67 pos cells within the def.1 Tregs.</s><s>Gating and Kaplan-Meier curves are depicted in b for pretreatment values of Foxp3 hi CD45RA neg def.1 Tregs and c for pretreatment values of Ki67 pos def.1 Tregs.</s><s>Gates for Foxp3 hi CD45RA neg and Ki67 pos were set as shown in the FACS plots.</s><s>Patients were grouped into two groups based on the median of the total population, i.e., into a group of patients with frequencies that were below the median (dotted line) or with frequencies above the median (solid line) for the indicated parameter, after which survival analysis was performed.</s><s>Number of patients and corresponding OS for each group is given.</s><s>Statistical analysis was performed by log-rank testing, and differences were considered significant when p &lt; 0.05</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Treg marker list generated after inquiry among workshop participants Number of participants (of total) who opted for inclusion of the indicated marker.</s><s>From 10 participants we received a response to our request in writing to generate a marker list indicating what markers they would like to add, in what order and context (tissue or site specific?)</s><s>and why Order a</s></p></div></figDesc><table><row><cell>Comment</cell></row><row><cell>Location</cell></row><row><cell>Expression</cell></row><row><cell>Marker</cell></row></table><note><p><s>a Order based on the number of participants who would like to add the indicated marker b</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc><div><p><s>Proposed marker set a Proposed order based on the outcome of the CIP workshop on the detection and functional testing of (antigen specific) regulatory T cells, subsequent discussions with leading experts in the field and data presented here</s></p></div></figDesc><table><row><cell cols="2">Order a Marker</cell><cell>Expression</cell><cell>Location</cell><cell>Advice</cell><cell>Comment</cell></row><row><cell>1</cell><cell>CD3</cell><cell>Directly ex vivo</cell><cell cols="2">Cell surface Essential</cell></row><row><cell>2</cell><cell>CD4</cell><cell>Directly ex vivo</cell><cell cols="2">Cell surface Essential</cell></row><row><cell>3</cell><cell>CD25</cell><cell>Directly ex vivo</cell><cell cols="2">Cell surface Essential</cell></row><row><cell>4</cell><cell>Foxp3</cell><cell>Directly ex vivo</cell><cell cols="2">Intranuclear Essential</cell></row><row><cell>5</cell><cell>CD127</cell><cell>Directly ex vivo; low/absent</cell><cell cols="2">Cell surface Essential</cell></row><row><cell>6</cell><cell>Ki67</cell><cell>Directly ex vivo</cell><cell cols="3">Intranuclear Highly recommended In recently activated/proliferating Tregs</cell></row><row><cell>7</cell><cell>CD45RA</cell><cell>Directly ex vivo</cell><cell cols="3">Cell surface Highly recommended Discriminates between naïve and TCR-</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>triggered Tregs</cell></row><row><cell>8</cell><cell>CTLA4</cell><cell>Directly ex vivo</cell><cell cols="2">Intracellular Optional</cell><cell>On (previously) activated Tregs</cell></row><row><cell>9</cell><cell>Helios</cell><cell>Directly ex vivo</cell><cell cols="2">Intranuclear Optional</cell><cell>Superior to CD25/CD127 in autoimmune</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>conditions (such as SLE)</cell></row><row><cell>10</cell><cell>CD39</cell><cell>Directly ex vivo</cell><cell cols="2">Cell surface Optional</cell><cell>Present on suppressive Tregs</cell></row><row><cell>11</cell><cell cols="2">LAP/GARP Upon activation (&gt;24 h) on PBMC/</cell><cell cols="2">Intracellular Optional</cell><cell>On activated Tregs</cell></row><row><cell></cell><cell></cell><cell>directly ex vivo on TIL</cell><cell></cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We would like to acknowledge Dr. David Murdoch for his thoughtful criticisms.</s><s>Saskia J.A.M. Santegoets and Sjoerd H. van</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion and discussion</head><p><s>The unambiguous enumeration of Tregs by flow cytometry is hampered by (a) the inability to directly measure their function and (b) the absence of an exclusive, highly specific marker.</s><s>Reaching consensus on an essential marker set for Treg enumeration with the currently available markers involves a number of considerations.</s><s>First, the essential marker set should be able to identify a population of cells that in addition to the essential Treg-defining markers also express other Treg-associated markers but do not produce IFNγ and IL-2 <ref type="bibr">[12,</ref><ref type="bibr">13,</ref><ref type="bibr" target="#b36">26]</ref>.</s><s>Secondly, as there are currently three Treg definitions used in the field <ref type="bibr">[8]</ref><ref type="bibr" target="#b19">[9]</ref><ref type="bibr" target="#b20">[10]</ref><ref type="bibr">[11]</ref><ref type="bibr">[12]</ref><ref type="bibr" target="#b36">26]</ref>, the cell population identified should be highly specific and include at least the same population of Tregs by all three definitions.</s><s>Third, the proposed marker set should allow for Conflict of interest Alexander Scheffold is a consultant to Miltenyi Biotec and holds several patents on the use of CD154 and CD137 for antigen-specific T cell analysis.</s><s>All other authors have no conflicts of interest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Appendix</head><p><s>Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),</s><s>which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">Anfossi-Platine Pharma Services</title>
		<editor>J. Albrecht-Helmholtz Zentrum München</editor>
		<imprint>
			<pubPlace>Munich, Germany 2. N; Lyon, France</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">A. ten Brinke-Sanquin</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Brix-Immudex</surname></persName>
		</author>
		<imprint>
			<pubPlace>Copenhagen, Denmark</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Germany. * Current affiliation: Medigene Immunotherapies GmbH</title>
		<author>
			<persName><forename type="first">J</forename><surname>Eckl-Helmholtz Zentrum München</surname></persName>
		</author>
		<imprint>
			<pubPlace>Munich; Planegg/Martinsried, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m">Center for Cancer Immune Therapy, Herlev</title>
				<meeting><address><addrLine>Denmark</addrLine></address></meeting>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Inderberg Suso-Oslo University Hospital</title>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
		<imprint>
			<pubPlace>Oslo, Norway</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Jacobs</surname></persName>
		</author>
		<imprint>
			<pubPlace>Nijmegen, The Netherlands</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Radboud University Medical Centre</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<author>
			<persName><forename type="first">D</forename><surname>Maurer</surname></persName>
		</author>
		<title level="m">Immatics Biotechnologies GmbH</title>
				<meeting><address><addrLine>Tübingen, Germany</addrLine></address></meeting>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">* Current affiliation: Medigene Immunotherapies GmbH</title>
		<author>
			<persName><forename type="first">T</forename><surname>Van Oorschot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">The Netherlands 18. D. Schendel-Helmholtz Zentrum</title>
				<meeting><address><addrLine>Nijmegen; München, Munich, Germany; Planegg/Martinsried, Germany; Herlev, Denmark</addrLine></address></meeting>
		<imprint>
			<date>19</date>
		</imprint>
		<respStmt>
			<orgName>Nijmegen Center for Molecular Life Sciences (NCMLS), Radboud University Medical Center</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">F</forename><surname>Toulza</surname></persName>
		</author>
		<imprint>
			<pubPlace>London, UK</pubPlace>
		</imprint>
		<respStmt>
			<orgName>London School of Hygiene &amp;Tropical Medicine</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Visser-Sanquin</surname></persName>
		</author>
		<imprint>
			<pubPlace>Amsterdam, The Netherlands References</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Regulatory T-cells in autoimmune diseases: challenges, controversies and-yet-unanswered questions</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Grant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Liberal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mieli-Vergani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vergani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Longhi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Autoimmun Rev</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="105" to="116" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Smigiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Srivastava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Stolley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Campbell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Rev</title>
		<imprint>
			<biblScope unit="volume">259</biblScope>
			<biblScope unit="page" from="40" to="59" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Whiteside</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol Immunother</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="67" to="72" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Tumor-specific regulatory T cells in cancer patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Piersma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Welters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Van Der Burg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Immunol</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="241" to="249" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">T-regulatory cells in tumour-specific vaccination strategies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Welters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Piersma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Van Der Burg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Biol Ther</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1365" to="1379" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects</title>
		<author>
			<persName><forename type="first">U</forename><surname>Petrausch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Poehlein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Twitty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Assmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Puri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Lacelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Moudgil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Maston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cardenas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Haley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Akporiaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Weinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rosenheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Crocenzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Curti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Urba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Fox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Mol Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="673" to="682" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">What are regulatory T cells (Treg) regulating in cancer and why?</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Whiteside</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Cancer Biol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="327" to="334" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Anti-CCR4 mAb selectively depletes effector-type FoxP3+ CD4+ regulatory T cells, evoking antitumor immune responses in humans</title>
		<author>
			<persName><forename type="first">D</forename><surname>Sugiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Maeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nishioka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tanemura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Katayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ezoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kanakura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fukumori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Karbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Jager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sakaguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="17945" to="17950" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells</title>
		<author>
			<persName><forename type="first">W</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Putnam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Xu-Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Szot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Gottlieb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kapranov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Gingeras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fazekas</forename><surname>De St</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Clayberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Soper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Ziegler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Bluestone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope unit="page" from="1701" to="1711" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells</title>
		<author>
			<persName><forename type="first">N</forename><surname>Seddiki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Santner-Nanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Martinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zaunders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sasson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Landay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Solomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Selby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kelleher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fazekas</forename><surname>De St</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope unit="page" from="1693" to="1700" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor</title>
		<author>
			<persName><forename type="first">M</forename><surname>Miyara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yoshioka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kitoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Niwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Parizot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Taflin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Heike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Valeyre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mathian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nakahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Amoura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gorochov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sakaguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="899" to="911" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The percentage of FoxP3+ Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">A</forename><surname>Golding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hasni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Illei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Shevach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="2898" to="2906" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Thornton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Korty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Q</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Wohlfert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Belkaid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Shevach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="3433" to="3441" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Generation and accumulation of immunosuppressive adenosine by human CD4+ CD25highFOXP3+ regulatory T cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mandapathil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hilldorfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Szczepanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Czystowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Szajnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gorelik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Whiteside</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="page" from="7176" to="7186" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Loza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>O'rourke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">U</forename><surname>Khan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Immunol</title>
		<imprint>
			<biblScope unit="volume">271</biblScope>
			<biblScope unit="page" from="110" to="117" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">A harmonized approach to intracellular cytokine staining gating: results from an international multiconsortia proficiency panel conducted by the cancer immunotherapy consortium (CIC/CRI)</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Mcneil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Britten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jaimes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Maecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Odunsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Matsuzaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Staats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thorpe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Janetzki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytometry A</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="728" to="738" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Harmonization of the intracellular cytokine staining assay</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Welters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gouttefangeas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Ramwadhdoebe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Letsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Ottensmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Britten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Van Der Burg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol Immunother</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="967" to="978" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Britten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Janetzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Butterfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gouttefangeas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Huber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kalos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Levitsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Maecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Melief</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Donnell-Tormey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Odunsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Old</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Ottenhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Ottensmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pawelec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Roederer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Roep</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">O</forename><surname>Romero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Der Burg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hoos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">T cell assays and MIATA: the essential minimum for maximum impact</title>
				<imprint>
			<date type="published" when="2012">2012</date>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1" to="2" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The simultaneous ex vivo detection of lowfrequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Meyering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Ramwadhdoebe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Stynenbosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Redeker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Kuppen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Melief</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Welters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Van Der Burg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol Immunother</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="1953" to="1963" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors</title>
		<author>
			<persName><forename type="first">M</forename><surname>Heusinkveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Welters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Van Poelgeest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Van Der Hulst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Melief</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Fleuren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Kenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Van Der Burg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="379" to="389" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>De Vos Van Steenwijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heusinkveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Ramwadhdoebe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Lowik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Van Der Hulst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Goedemans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Piersma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Kenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Van Der Burg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="2707" to="2717" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">The importance of Foxp3 antibody and fixation/permeabilization buffer combinations in identifying CD4+ CD25+ Foxp3+ regulatory T cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Law</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Hirschkorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Owen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Biswas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Norris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Lanteri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytometry A</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="1040" to="1050" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Association of two clones allows for optimal detection of human FOXP3</title>
		<author>
			<persName><forename type="first">P</forename><surname>Presicce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Moreno-Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Lages</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">I</forename><surname>Orsborn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Chougnet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytometry A</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="571" to="579" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Grant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bourcier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wallace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Conway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Seyfert-Margolis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Wallace</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytometry B Clin Cytom</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="69" to="78" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">OMIP-006: phenotypic subset analysis of human T regulatory cells via polychromatic flow cytometry</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Murdoch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Staats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Weinhold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytometry A</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="281" to="283" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">T</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sattler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Templin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kohler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Meisel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sawitzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Radbruch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hiepe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1549" to="1558" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression</title>
		<author>
			<persName><forename type="first">S</forename><surname>Deaglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Dwyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Usheva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Erat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Enjyoji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Linden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Oukka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Kuchroo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Strom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Robson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">204</biblScope>
			<biblScope unit="page" from="1257" to="1265" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Schuler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schilling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Harasymczuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Whiteside</surname></persName>
		</author>
		<title level="m">Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+</title>
				<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">FOXP3neg T-cell subsets in cancer patients</title>
	</analytic>
	<monogr>
		<title level="j">Eur J Immunol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1876" to="1885" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mandapathil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gorelik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Whiteside</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol Methods</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="55" to="63" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Separation of human CD4+ CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Schuler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Harasymczuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schilling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Whiteside</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol Methods</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="59" to="68" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Decreased CD127 expression on CD4+ T-cells and elevated frequencies of CD4+ CD25+ C</title>
		<author>
			<persName><forename type="first">M</forename><surname>Moniuszko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Glowinska-Olszewska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rusak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jeznach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Grubczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lipinska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Milewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Milewska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dabrowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Jablonska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kretowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gorska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bodzenta-Lukaszyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bossowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Dev Immunol</title>
		<imprint>
			<biblScope unit="volume">2013</biblScope>
			<biblScope unit="page">459210</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Welters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Kenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Piersma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Vloon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Lowik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Berends-Van Der Meer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Drijfhout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Valentijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Wafelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Oostendorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Fleuren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Offringa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Melief</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Van Der Burg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="178" to="187" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Welters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Kenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>De Vos Van Steenwijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Lowik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Berends-Van Der Meer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Essahsah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Stynenbosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Vloon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Ramwadhdoebe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Piersma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Van Der Hulst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Valentijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Fathers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Drijfhout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Franken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Oostendorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Fleuren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Melief</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Van Der Burg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="11895" to="11899" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion</title>
		<author>
			<persName><forename type="first">B</forename><surname>Kavanagh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>O'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Weinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Allison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Small</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="1175" to="1183" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latencyassociated peptide</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sharma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="122" to="130" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Landskron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Helland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Torgersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Aandahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Gjertsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bjorge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tasken</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol Immunother</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="337" to="347" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival</title>
		<author>
			<persName><forename type="first">S</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Weinschenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stenzl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zdrojowy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pluzanska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Szczylik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Staehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Brugger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Dietrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mendrzyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hilf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Schoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fritsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mahr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Vass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Trautwein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lewandrowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Flohr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pohla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Stanczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bronte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mandruzzato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Biedermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pawelec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Derhovanessian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamagishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hongo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Takaha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hirakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stevanovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Frisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mayer-Mokler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Rammensee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Reinhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Singh-Jasuja</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1254" to="1261" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">The fate of human Treg cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Battaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Roncarolo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="763" to="765" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Jie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gildener-Leapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Srivastava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Whiteside</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Ferris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="2629" to="2635" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">CD147 in regulatory T cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Landskron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tasken</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Immunol</title>
		<imprint>
			<biblScope unit="volume">282</biblScope>
			<biblScope unit="page" from="17" to="20" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">CD147 (Basigin/Emmprin) identifies FoxP3+ CD45RO+ CTLA4+ -activated human regulatory T cells</title>
		<author>
			<persName><forename type="first">T</forename><surname>Solstad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Bains</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Landskron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Aandahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Thiede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tasken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Torgersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="5141" to="5151" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Q</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ramsey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Unutmaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Shevach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="13445" to="13450" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Q</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hardwick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bebris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Illei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Shevach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="5125" to="5133" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Highly prevalent colorectal cancer-infiltrating LAP(+) Foxp3(−) T cells exhibit more potent immunosuppressive activity than Foxp3(+) regulatory T cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Scurr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ladell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Besneux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Christian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hockey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Smart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bridgeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hargest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gallimore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Godkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mucosal Immunol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="428" to="439" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">FOXP3 and GARP (LRRC32): the master and its minion</title>
		<author>
			<persName><forename type="first">M</forename><surname>Probst-Kepper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Buer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Direct</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">8</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells</title>
		<author>
			<persName><forename type="first">T</forename><surname>Duhen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Duhen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lanzavecchia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sallusto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Campbell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="4430" to="4440" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Expression of Helios in peripherally induced Foxp3+ regulatory T cells</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Gottschalk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Corse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Allison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">188</biblScope>
			<biblScope unit="page" from="976" to="980" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Helios+ and Helios− cells coexist within the natural FOXP3+ T regulatory cell subset in humans</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Himmel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Macdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Steiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Levings</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">190</biblScope>
			<biblScope unit="page" from="2001" to="2008" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Kniemeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schonbrunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sawitzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Assenmacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rietschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Steinbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Cornely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Brakhage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Scheffold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mucosal Immunol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="916" to="928" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigenreactive natural Foxp3+ Treg</title>
		<author>
			<persName><forename type="first">A</forename><surname>Schoenbrunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Frentsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kohler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Keye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dooms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Moewes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Loddenkemper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sieper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Romagnani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Matzmohr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">189</biblScope>
			<biblScope unit="page" from="5985" to="5994" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">CD49d provides access to &quot;untouched&quot; human Foxp3+ Treg free of contaminating effector cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kleinewietfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Starke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Di</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Borsellino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Battistini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rotzschke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Falk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="827" to="836" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Battaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Buzzonetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baranello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ferrandina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Martinelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fanfani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Scambia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fattorossi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol Immunother</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1363" to="1373" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Delgoffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Woo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Turnis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Gravano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Guy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Overacre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Bettini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Finkelstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bonnevier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Workman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Vignali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">501</biblScope>
			<biblScope unit="page" from="252" to="256" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Neuropilin-1 is not a marker of human Foxp3+ Treg</title>
		<author>
			<persName><forename type="first">P</forename><surname>Milpied</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Renand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bruneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Mendes-Da-Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jacquelin</forename><forename type="middle">S</forename><surname>Asnafi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rubio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Macintyre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lepelletier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hermine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Immunol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1466" to="1471" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
